

Appl. No. : 10/005,305
Filed : November 2, 2001

AMENDMENTS TO THE CLAIMS

Please cancel Claims 1-4 and 6-10 without prejudice, amend Claims 5 and 11-13, and add Claim 14 as follows:

1-4 (Canceled)

5. (Currently amended) A method of screening for agonists and antagonists making a pharmaceutical product comprising:

providing a peptide agent having a sequence corresponding to T20/DPI78 of SEQ ID NO:197 or a carboxy truncation, amino truncation, or internal truncation thereof having a sequence selected from the group consisting of SEQ ID NO:2-96 T20/DPI78, T21/DPI07, or a conservative variant or functional fragment thereof;

providing a cell having thereon a formyl peptide receptor (FPR) an FPR member that interacts with said peptide agent;

contacting said peptide agent with said cell under conditions that allow said peptide agent to interact with said FPR member on said cell;

identifying the presence or absence of signal transduction generated in response to the interaction of said peptide agent with said FPR member; and

characterizing said peptide agent as being an incorporating said peptide agent into said pharmaceutical product, wherein said pharmaceutical product is an FPR member antagonist if said signal transduction is identified as being absent or characterizing said peptide agent as being an , and wherein said pharmaceutical product in an FPR member agonist if said signal transduction is identified as being present.

6-10 (Canceled)

2 11. (Currently amended) The method of Claim 5, wherein said peptide agent is a carboxy truncation, amino truncation, or internal truncation functional fragment of T20/DPI78 or T21/DPI07 having a sequence selected from the group consisting of SEQ ID NO:2-96 SEQ ID NO:2-196.

3 12. (Currently amended) The method of Claim 5, wherein said peptide agent is the amino truncation a functional fragment of T20/DPI78 that lacks 3, 5, 7, or 12 amino acids at the N-terminus having a sequence selected from the group consisting of SEQ ID NO: 55, 60, 62, and 64.

Appl. No. : 10/005,305
Filed : November 2, 2001

⁴ 13. (Currently amended) The method of Claim ¹5, wherein said peptide agent is T20/DP178 ~~of having~~ SEQ ID NO:197.

⁵ 14. (New) The method of any of Claims ¹5, ²11, ³12, or ⁴13 further comprising incorporating said agonist or antagonist into a composition.